Lugano, Switzerland – January 8, 2025 – Helsinn Group ("Helsinn"), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive ...
Lugano, Switzerland – February 11th, 2026 – Helsinn Healthcare SA ("Helsinn"), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and MagnaPharm, a leading ...
MGI Pharma’s anti-emetic drug Aloxi has its first ever consumer effort, featuring print ads aimed at women cancer patients. The ads, by inVentiv agency GSW Worldwide, aim to raise awareness of Aloxi, ...
The European approval of ALOXI ® for paediatric use follows the FDA approval in May 2014 of ALOXI ® for paediatric use in the US Helsinn Group, the Swiss Group focused on building quality cancer care, ...
DRL will be permitted to market a 505(j) generic version of Aloxi in the US on September 30, 2018 or earlier under certain circumstances Switzerland-based pharma company Helsinn Healthcare has entered ...
WASHINGTON (Reuters) - The U.S. Supreme Court on Tuesday refused to revive Swiss drug company Helsinn Healthcare S.A.'s patent on the lucrative anti-nausea drug Aloxi in a victory for Teva ...
MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, and its partner HELSINN HEALTHCARE SA, a privately owned Swiss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results